PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Not yet recruitingThis study tests the long-term safety of HRS-5965 capsules in 380 adults with primary IgA nephropathy, a kidney disease. Participants will take the drug and be monitored for side effects, as well as changes in urine protein and kidney function. The goal is to see if HRS-5965 can …
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug aims to reduce kidney damage in IgAN patients
Disease control Not yet recruitingThis study tests an experimental drug called FXS6837 in 60 adults with IgA nephropathy, a kidney disease. Participants will receive either the drug or a placebo for about 6 months. The main goal is to see if the drug lowers protein in the urine, a sign of kidney damage.
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC